Efficacy of Nylidrin Hydrochloride in the Treatment of Cognitive Impairment in the Elderly*

Abstract
A double-blind study was conducted on the effects of nylidrin hydrochloride [NH] vs. placebo in 60 patients with mild to moderate symptoms of chronic brain syndrome. Their ages ranged from 65-99 yr. NH (a vasodilator) is a relatively safe therapeutic agent and more effective than placebo in ameliorating the symptoms of cognitive impairment associated with aging, on both a short-term (3 mo.) and a long-term (9 mo.) basis. In a dosage of 24 mg daily it reached its peak effectiveness after 3 mo. of use.